Drugmaker Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen, ending one of the controversies over the soaring price of the emergency allergy injection. The settlement with the Department of Justice follows news that EpiPen has been incorrectly classified since late 1997 as a generic product under...